• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

CLOFIBRATE Drug Record

  • Summary
  • Interactions
  • Claims
  • CLOFIBRATE chembl:CHEMBL565 Approved

    Alternate Names:

    NSC-79389
    CLOFIBRATE
    ICI-28257
    AY-61123
    ATROMID
    ATROMID-S
    CHLORFENISATE
    2-(P-CHLOROPHENOXY)-2-METHYLPROPIONIC ACID ETHYL ESTER
    ETHYL 2-(P-CHLOROPHENOXY)ISOBUTYRATE
    ALPHA-(P-CHLOROPHENOXY)ISOBUTYRIC ACID, ETHYL ESTER
    ATROMID-S®
    EPIB
    LIPOFACTON
    ETHYL CHLOROPHENOXYISOBUTYRATE
    CLOFIBRATUM
    LIPRIN
    ALPHA-P-CHLOROPHENOXYISOBUTYRYL ETHYL ESTER
    CLOFIBRATO
    ELPI
    2-(4-CHLOROPHENOXY)-2-METHYLPROPANOIC ACID ETHYL ESTER
    ETHYL CLOFIBRATE
    chemidplus:637-07-0
    drugbank:00636
    rxcui:2594
    pubchem.compound:2796
    chembl:CHEMBL565

    Drug Info:

    FDA Approval 1967
    Drug Class small molecule
    Drug Indications Anticholesteremic Agents
    Drug Class anticholesteremic agents
    Year of Approval 1967
    (4 More Sources)

    Publications:

    Zhang X et al., 2000, Promoter activity and regulation of the CYP4F2 leukotriene B(4) omega-hydroxylase gene by peroxisomal proliferators and retinoic acid in HepG2 cells., Arch Biochem Biophys
    Hsu MH et al., 2007, Regulation of human cytochrome P450 4F2 expression by sterol regulatory element-binding protein and lovastatin., J Biol Chem
    Parker RS et al., 2004, Discovery, characterization, and significance of the cytochrome P450 omega-hydroxylase pathway of vitamin E catabolism., Ann N Y Acad Sci
    Sontag TJ et al., 2002, Cytochrome P450 omega-hydroxylase pathway of tocopherol catabolism. Novel mechanism of regulation of vitamin E status., J Biol Chem
    Parker RS et al., 2000, Cytochrome P4503A-dependent metabolism of tocopherols and inhibition by sesamin., Biochem Biophys Res Commun
    Yamazaki et al., 2005, Effects of fibrates on human organic anion-transporting polypeptide 1B1-, multidrug resistance protein 2- and P-glycoprotein-mediated transport., Xenobiotica
    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
    MacDonald ML et al., 2006, Identifying off-target effects and hidden phenotypes of drugs in human cells., Nat Chem Biol
    Casas et al., 2000, A 45 kDa protein related to PPARgamma2, induced by peroxisome proliferators, is located in the mitochondrial matrix., FEBS Lett.
    Palkar et al., 2010, Effect of prenatal peroxisome proliferator-activated receptor alpha (PPARalpha) agonism on postnatal development., Toxicology
    Kömüves et al., 2000, Stimulation of PPARalpha promotes epidermal keratinocyte differentiation in vivo., J. Invest. Dermatol.
    Gelosa et al., 2010, Peroxisome proliferator-activated receptor {alpha} agonism prevents renal damage and the oxidative stress and inflammatory processes affecting the brains of stroke-prone rats., J. Pharmacol. Exp. Ther.
    Murata et al., 2000, Stimulation by eicosapentaenoic acids of leptin mRNA expression and its secretion in mouse 3T3-L1 adipocytes in vitro., Biochem. Biophys. Res. Commun.
    Barclay et al., 1999, Modulation of cytochrome P-450 gene expression in endotoxemic mice is tissue specific and peroxisome proliferator-activated receptor-alpha dependent., J. Pharmacol. Exp. Ther.
    Hunt et al., 2000, Involvement of the peroxisome proliferator-activated receptor alpha in regulating long-chain acyl-CoA thioesterases., J. Lipid Res.
    Lefevre et al., 2001, Effects of polyunsaturated fatty acids and clofibrate on chicken stearoyl-coA desaturase 1 gene expression., Biochem. Biophys. Res. Commun.
    Brandes et al., 1990, Induction of fatty acid binding protein by peroxisome proliferators in primary hepatocyte cultures and its relationship to the induction of peroxisomal beta-oxidation., Biochim. Biophys. Acta
    Long et al., 1996, Regulation of GLUT4 gene expression by arachidonic acid. Evidence for multiple pathways, one of which requires oxidation to prostaglandin E2., J. Biol. Chem.
  • CLOFIBRATE   CYP4F2

    Interaction Score: 3.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10860554 17142457 15753130 11997390 11061988


    Sources:
    PharmGKB

  • CLOFIBRATE   FABP1

    Interaction Score: 2.75

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    2328261


    Sources:
    NCI

  • CLOFIBRATE   SCD

    Interaction Score: 1.65

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11162472


    Sources:
    NCI

  • CLOFIBRATE   CFL1

    Interaction Score: 1.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16680159


    Sources:
    DTC

  • CLOFIBRATE   PPARA

    Interaction Score: 0.72

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Trial Name -
    Novel drug target Established target
    Mechanism of Interaction Peroxisome proliferator-activated receptor alpha agonist

    PMIDs:
    10922459 20637823 10951268 20671072 10753628 10454501 10787442


    Sources:
    TdgClinicalTrial ChemblInteractions TEND

  • CLOFIBRATE   LPL

    Interaction Score: 0.23

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • CLOFIBRATE   SLC2A4

    Interaction Score: 0.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8557642


    Sources:
    NCI

  • CLOFIBRATE   JUN

    Interaction Score: 0.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16680159


    Sources:
    DTC

  • CLOFIBRATE   CDK1

    Interaction Score: 0.17

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16680159


    Sources:
    DTC

  • CLOFIBRATE   SLCO1B1

    Interaction Score: 0.16

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16316932


    Sources:
    NCI

  • CLOFIBRATE   TP53

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16680159


    Sources:
    DTC

  • CLOFIBRATE   CYP2C19

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • CLOFIBRATE   CYP1A2

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • CLOFIBRATE   CYP2D6

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • CLOFIBRATE   CYP3A4

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • TEND: CLOFIBRATE

    • Version: 01-August-2011

    Alternate Names:
    CLOFIBRATE Primary Drug Name

    Drug Info:
    Year of Approval 1967
    Drug Class anticholesteremic agents

    Publications:

  • TdgClinicalTrial: CLOFIBRATE

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications Anticholesteremic Agents
    Drug Class small molecule
    FDA Approval 1967

    Publications:

  • NCI: CLOFIBRATE

    • Version: 14-September-2017

    Alternate Names:
    C378 NCI drug code

    Drug Info:

    Publications:
    Lefevre et al., 2001, Effects of polyunsaturated fatty acids and clofibrate on chicken stearoyl-coA desaturase 1 gene expression., Biochem. Biophys. Res. Commun.
    Brandes et al., 1990, Induction of fatty acid binding protein by peroxisome proliferators in primary hepatocyte cultures and its relationship to the induction of peroxisomal beta-oxidation., Biochim. Biophys. Acta
    Long et al., 1996, Regulation of GLUT4 gene expression by arachidonic acid. Evidence for multiple pathways, one of which requires oxidation to prostaglandin E2., J. Biol. Chem.

  • DTC: CLOFIBRATE

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL565 ChEMBL Drug ID

    Drug Info:

    Publications:
    MacDonald ML et al., 2006, Identifying off-target effects and hidden phenotypes of drugs in human cells., Nat Chem Biol
    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

  • PharmGKB: clofibrate

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Zhang X et al., 2000, Promoter activity and regulation of the CYP4F2 leukotriene B(4) omega-hydroxylase gene by peroxisomal proliferators and retinoic acid in HepG2 cells., Arch Biochem Biophys
    Parker RS et al., 2004, Discovery, characterization, and significance of the cytochrome P450 omega-hydroxylase pathway of vitamin E catabolism., Ann N Y Acad Sci
    Parker RS et al., 2000, Cytochrome P4503A-dependent metabolism of tocopherols and inhibition by sesamin., Biochem Biophys Res Commun

  • TTD: Clofibrate

    • Version: 2020.06.01

    Alternate Names:
    D0J5DC TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL565

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL565

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21